Nikko Asset Management Americas Inc. Sells 132,966 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX)

Nikko Asset Management Americas Inc. reduced its stake in Repare Therapeutics Inc. (NASDAQ:RPTX) by 53.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 116,249 shares of the company’s stock after selling 132,966 shares during the quarter. Nikko Asset Management Americas Inc.’s holdings in Repare Therapeutics were worth $152,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vontobel Holding Ltd. raised its stake in shares of Repare Therapeutics by 45.8% in the 4th quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company’s stock valued at $46,000 after purchasing an additional 11,000 shares during the period. Barclays PLC grew its holdings in shares of Repare Therapeutics by 1,471.7% during the third quarter. Barclays PLC now owns 8,330 shares of the company’s stock worth $29,000 after buying an additional 7,800 shares in the last quarter. Finally, Stifel Financial Corp grew its holdings in shares of Repare Therapeutics by 36.4% during the third quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock worth $178,000 after buying an additional 13,800 shares in the last quarter. 85.09% of the stock is owned by institutional investors and hedge funds.

Repare Therapeutics Stock Up 3.2 %

RPTX stock opened at $1.14 on Tuesday. The company has a market cap of $48.25 million, a price-to-earnings ratio of -0.57 and a beta of 0.87. Repare Therapeutics Inc. has a twelve month low of $1.06 and a twelve month high of $5.52. The business has a 50 day moving average price of $1.23 and a two-hundred day moving average price of $2.33.

Repare Therapeutics (NASDAQ:RPTX) last issued its earnings results on Monday, March 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.10. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 40.87%. On average, equities research analysts anticipate that Repare Therapeutics Inc. will post -2.04 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on RPTX shares. Lifesci Capital reaffirmed a “market perform” rating on shares of Repare Therapeutics in a research report on Friday, December 13th. Stifel Nicolaus reduced their target price on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating for the company in a report on Friday, December 13th. HC Wainwright lowered their price target on shares of Repare Therapeutics from $10.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Finally, Bloom Burton cut shares of Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.